CRISPR-Cas9 correction of OPA1 c.1334G>A: p.R445H restores mitochondrial homeostasis in dominant optic atrophy patient-derived iPSCs: Molecular Therapy - Nucleic Acids
Por um escritor misterioso
Descrição
CRISPR-Cas9 editing of a TNPO3 mutation in a muscle cell model of
CRISPR-AsCas12a Efficiently Corrects a GPR143 Intronic Mutation in
Melatonin Repairs Osteoporotic Bone Defects in Iron-Overloaded
Characterisation of a novel OPA1 splice variant resulting in
PDF) Optimized OPA1 Isoforms 1 and 7 Provide Therapeutic Benefit
Characterisation of a novel OPA1 splice variant resulting in
PDF) Modelling autosomal dominant optic atrophy associated with
OPA1 Mutation and Late‐Onset Cardiomyopathy: Mitochondrial
CRISPR-AsCas12a Efficiently Corrects a GPR143 Intronic Mutation in
PDF) Establishing induced pluripotent stem cell lines from two
CRISPR/Cas9-Mediated Gene Correction in Osteopetrosis Patient
Understanding the molecular basis and pathogenesis of hereditary
CRISPR-Cas9 correction of OPA1 c.1334G>A: p.R445H restores
